- Home
- PAAS vs NBIX Comparison
PAAS vs NBIX Comparison
Compare PAAS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAAS | NBIX |
|---|---|---|
| Founded | 1994 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 14.4B |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PAAS | NBIX |
|---|---|---|
| Price | $44.19 | $155.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $47.00 | ★ $173.79 |
| AVG Volume (30 Days) | ★ 5.8M | 969.9K |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | 1.73 | ★ 4.19 |
| Revenue | ★ $3,254,800,000.00 | $2,682,700,000.00 |
| Revenue This Year | $27.28 | $23.76 |
| Revenue Next Year | $21.01 | $18.01 |
| P/E Ratio | ★ $29.46 | $37.10 |
| Revenue Growth | ★ 21.75 | 19.61 |
| 52 Week Low | $19.80 | $84.23 |
| 52 Week High | $46.60 | $157.67 |
Technical Indicators
Market Signals| Indicator | PAAS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 64.81 |
| Support Level | $43.44 | $150.26 |
| Resistance Level | $46.60 | $154.35 |
| Average True Range (ATR) | 1.84 | 4.16 |
| MACD | 0.58 | 1.07 |
| Stochastic Oscillator | 79.93 | 93.25 |
Price Performance
Historical ComparisonAbout PAAS Pan American Silver Corp.
Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.